Cytotheryx, a preclinical cell therapy company developing cell-based treatments for liver disease, announced a lead term sheet from Ouroboros Family Founders Fund I, LP for its $60 million Series A financing, positioning the Company to advance multiple programs into the clinic. In parallel, Cytotheryx secured additional debt financing from QRS Investments, LLC to expand its real estate footprint, enable GMP manufacturing capacity and support continued operational scale-up.